BMO Capital Markets assumed coverage on shares of Inflarx (NASDAQ:IFRX) in a research report report published on Monday morning. The firm issued an outperform rating and a $31.00 price objective on the stock.
A number of other brokerages have also weighed in on IFRX. Leerink Swann began coverage on Inflarx in a research note on Monday. They issued an outperform rating and a $31.00 target price on the stock. J P Morgan Chase & Co began coverage on Inflarx in a research note on Monday. They issued an overweight rating and a $30.00 target price on the stock.
Shares of Inflarx (NASDAQ:IFRX) traded down $1.08 during midday trading on Monday, reaching $17.58. The company’s stock had a trading volume of 92,900 shares, compared to its average volume of 57,095. Inflarx has a fifty-two week low of $14.47 and a fifty-two week high of $22.48.
COPYRIGHT VIOLATION NOTICE: “Inflarx (IFRX) Research Coverage Started at BMO Capital Markets” was reported by Stock Observer and is owned by of Stock Observer. If you are reading this news story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this news story can be read at https://www.thestockobserver.com/2017/12/07/inflarx-ifrx-research-coverage-started-at-bmo-capital-markets.html.
Inflarx Company Profile
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company’s primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases.
Receive News & Ratings for Inflarx NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inflarx NV and related companies with MarketBeat.com's FREE daily email newsletter.